Letters Section Editor: Robert M. Golub,
MD, Senior Editor.
In Reply: We agree with some of the comments
raised by Dr Osman and colleagues, as we noted in the discussion of the limitations
of our study. Among available glycoprotein IIb/IIIa inhibitors, Abciximab
is the agent of choice in the context of primary intervention. When administered
in the catheterization laboratory, abciximab, which provides rapid and complete
antiplatelet effect, has been shown to be superior to tirofiban when administered
as a 10-μg/kg bolus.1 When tirofiban is
administered at this dose, the level of platelet inhibition reached after
10 to 15 minutes is suboptimal compared to that achieved using abciximab.
Valgimigli M. Tirofiban Plus Sirolimus-Eluting Stent vs Abciximab Plus Bare-Metal
Stent—Reply. JAMA. 2005;294(13):1616-1618. doi:10.1001/jama.294.13.1617-b